Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vitreoretinal Technologies has started the enrollment of the first patients in a multinational Phase III clinical trial for evaluation of the safety and efficacy of Vitreosolve for diabetic retinopathy patients.
Subscribe to our email newsletter
The first patients were enrolled and treated at clinical sites both in the US and India. This study is the first one of two pivotal studies required by the FDA for the application of a new drug application.
Hampar Karageozian, founder and CEO of Vitreoretinal, said: “This is a validation of our unique strategy for drug development and management of the regulatory process.”